Periodic Reporting for period 1 - BactDrugConj (Bacteriocin-mediated Import of Active Molecules)
Reporting period: 2022-05-03 to 2024-05-02
The opportunistic pathogen Pseudomonas aeruginosa is a major problem in hospitals. This Gram-negative bacterial pathogen causes ventilator-associated pneumonia, complicated urinary tract infection, and post-operative infections of soft tissues. These bacteria represent a threat for immunocompromised patients, where infections following surgery can be fatal.1 Besides, P. aeruginosa chronical infections are often deadly for patients suffering from rare diseases, such as cystic fibrosis (CF). P. aeruginosa colonises the lungs of CF patients resulting in higher rates of mortality than the disease itself. Some strains of P. aeruginosa are resistant to nearly all of the available antibiotics, both due to their capacity to acquire resistance genes via horizontal transfer and their intrinsic resistance mechanisms. This project will explore biotechnological approaches against antibioresistance in P.aeruginosa.
Bacteriocins are ribosomally synthesised antimicrobial peptides that are produced by various bacteria to kill or inhibit growth of their competitors during the fight for resources. They can be effective against antibiotic-resistant bacteria. Pyocins are bacteriocins secreted by P. aeruginosa to kill closely related Pseudomonas strains. They simply highjack the nutrient-import systems of vulnerable bacteria to make their way into the cell. However, their killing ¬potential is low compared to some chemically-synthesised antibiotics. Therefore, coupling the vector properties of bacteriocins and the cytotoxicity of synthetic drugs represents a novel and potentially revolutionary antibacterial chemotherapeutic approach following a Trojan Horse strategy.
The protein has been produced but the access to it hasn't be given by the previous supervisor or this fellowship. Therefore, no coupling has been achieved even though some antibiotics were available.